Versican expression in canine carcinomas in benign mixed tumours: Is there an association with clinical pathological factors, invasion and overall survival?

BMC Veterinary Research

Volumn 8, Issue , 2012, Pages

  Damasceno, Karine A ^a   Bertagnolli, Angélica C ^b   Estrela Lima, Alessandra ^c   Ribeiro, Lorena G R ^c   Rabelo, Bruna S ^a   Campos, Cecília B ^a   Barros, André L B ^a   Cassali, Geovanni D ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEPAGRO Animal Health   (Brazil)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Canine; Carcinoma; Invasion; Mixed tumour; Versican

Indexed keywords

VERSICAN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CARCINOMA; CELL ADHESION; CELL PROLIFERATION; DOG; DOG DISEASE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; LYMPH NODE; MALE; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; TUMOR INVASION;

ANIMALS; CARCINOMA; CELL ADHESION; CELL PROLIFERATION; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; LYMPH NODES; MALE; MAMMARY NEOPLASMS, ANIMAL; NEOPLASM INVASIVENESS; VERSICANS;

MLCS; MLOWN;

EID: 84867620540     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-8-195     Document Type: Article

References (46)

1. Peleteiro MC. Tumores mamários na cadela e na gata. Rev Port Ciênc Vet 1994, 89: 509:10-29.
2. Morrison WB. Cancers in dogs and cats, Medical and surgical management 1998, 785. Philadelphia: Willians e Wilkins.
3. Cassali GD, Melo BM, Madureira N, Ferreira E, Bertagnolli AC, Ribeiro GM, Campos CB. Mammary gland diagnosis of the Laboratory of Comparative Pathology - UFMG, from 2000 to 2008. Clínica Veterinária 2009, 14:173-173. 3505957, 23259143.
4. Estrela-Lima A, Araújo MSS, Costa-Neto JM, Teixeira-Carvalho A, Barrouin-Melo SM, Cardoso SV, Martins-Filho OA, Serakides R, Cassali GD. Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 2010, 10:1-14. 10.1186/1471-2407-10-1, 2824708, 20047689.
5. Mitchell L, Iglesia FA, Wenkoff MS, Van D, Lumb G. Mammary tumors in dogs: survey of clinical and pathological characteristics. Can Vet J 1974, 15:131-138. 1696500, 4831371.
6. Moulton JE. Tumors of the mammary gland. Tumors in Domestic Animals 1990, 518-552. Berkeley, CA: University of California Press, Moulton JE, 3.
7. Perez-Alenza MD, Pena l, Castillo ND, Nieto AI. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract 2000, 41:287-291. 10.1111/j.1748-5827.2000.tb03203.x, 10976622.
8. Lavalle GE, Bertagnolli AC, Tavares WLF, Cassali GD. COX-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival. Vet Pathol 2009, 46:1275-1280. 10.1354/vp.08-VP-0226-C-FL, 19605908.
9. Cassali GD, Lavalle GE, De Nardi AB, Ferreira E, Bertagnolli AC, Estrela-Lima A, Alessi CA, Daleck CR, Salgado BS, Fernandes CG, Sobral RA, Amorim RL, Gamba CO, Damasceno KA, Auler PA, Magalhaes GM, Silva JO, Raposo JB, Ferreira AMR, Oliveira LO, Malm C, Zuccari DAPC, Tanaka NM, Ribeiro LR, Campos LC, Souza CM, Leite JS, Soares LMC, Cavalcanti MF, Fonteles ZGC, Schuch ID, Paniago J, Oliveira TS, Terra EM, Castanheira TLL, Felix AOC, Carvalho GD, Guim TN, Garrido E, Fernandes SC, Maia FCL, Dagli MLZ, Rocha NS, Fukumasu H, Grandi F, Machado JP, Silva SMMS, Bezerril JE, Frehse MS, Almeida ECP, Campos CB. Consensus for the diagnosis, prognosis and treatment of canine mammary tumours. Braz J Vet Pathol 2011, 4:153-180.
10. Moulton JE, Taylor DDN, Andersen AG. Canine MammaryTumors. Pathol Vet 1970, 7:289-320. 10.1177/030098587000700401, 4328309.
11. Genelhu MCLS, Cardoso SV, Gobbi H, Cassali GD. A comparative study between mixed-type tumours from human salivary and canine mammary glands. BMC Cancer 2007, 28:1-9.
12. Bertagnolli AC, Cassali GD, Genelhu MCLS, Costa FA, Oliveira JFC, Gonçalves PBD. Immunohistochemical expression of p63 and Np63 in mixed tumors of canine mammary glands and its relation with p53 expression. Vet Pathol 2009, 46:407-415. 10.1354/vp.08-VP-0128-C-FL, 19176510.
13. Bertagnolli AC, Ferreira E, Dias EJ, Cassali GD. Canine mammary mixed tumours: immunohistochemical expressions of EGFR and HER-2. Aust Vet J 2011, 89:312-317.
14. Erdélyi I, Nieskens DHM, Dijk JE, Vass L, Nederbragt H. Immunohistochemical evaluation of versican, in relation to chondroitin sulphate, in canine mammary tumors. Histol Histopathol 2003, 18:1067-1080.
15. Pukkila MJ, Kosunen AST, Virtaniemi JA, Kumpulainen EJ, Johansson RT, Kellokoski JK, Nuutinen J, Kosma VW. Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study. J Clin Pathol 2004, 57:735-739. 10.1136/jcp.2003.014589, 1770361, 15220367.
16. Yee AJM, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, Yang B. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 2007, 9:1-11.
17. Bode-Lesniewska B, Dours-Zimmermann MT, Odermatt BF, Briner J, Heitz PU, Zimmermann DR. Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem 1996, 44:303-312. 10.1177/44.4.8601689, 8601689.
18. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y. Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 2007, 18:269-274.
19. Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD, Horsfall DJ. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 2007, 282:10814-10825. 10.1074/jbc.M606991200, 17293599.
20. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, Horsfall DJ. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004, 10:2491-2498. 10.1158/1078-0432.CCR-03-0146, 15073129.
21. Erdélyi I, Van Asten AJAM, Van Dijk JE, Nederbragt H. Expression of versican in relation to chondrogenesis-related extracellular matrix components in canine mammary tumors. Histochem Cell Biol 2005, 124:139-149. 10.1007/s00418-005-0007-y, 16088379.
22. Ferreira E, Bertagnolli AC, Cavalcanti MF, Schmitt FC, Cassali GD. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. Vet Comp Oncol 2009, 7:230-235. 10.1111/j.1476-5829.2009.00193.x, 19891693.
23. Man YG, Tai L, Barner R, Vang R, Saenger JS, Shekitka KM, Bratthauer GL, Wheeler DT, Liang CY, Vinh TN, Strauss BL. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res 2003, 5:231-241.
24. Canavese G, Candelaresi G, Castellano I, Mano MP. Expression of proteoglycan versican in in situ breast lesions: Relations between stromal changes, histotype, and invasion. Pathol Res Pract 2011, 207:97-103. 10.1016/j.prp.2010.10.009, 21185131.
25. Yamagata M, Saga S, Kato M, Bernfield M, Kimata K. Selective distributions of proteoglycans and their ligands in pericellular matrix of cultured fibroblasts. Implications for their roles in cell-substratum adhesion. J Cell Sci 1993, 106:55-65.
26. Mukaratirwa S, Van Ederen AM, Gruys E, Nederbragt H. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion. J Comp Pathol 2004, 131:259-270. 10.1016/j.jcpa.2004.04.007, 15511534.
27. Adriance MC, Inman JL, Petersen OW, Bissell MJ. Myoepithelial cells: good fences make good neighbors. Breast Cancer Res 2005, 7:190-197. 10.1186/bcr1286, 1242144, 16168137.
28. Cavalcante RB, Lopes FF, Ferreira AS, Freitas RA, Souza LB. Immunohistochemical expression of vimentin, calponin and HHF-35 in salivary gland tumors. Braz Dent J 2007, 18:192-197. 10.1590/S0103-64402007000300003, 18176708.
29. Brown LF, Guidi AJ, Schnitt SJ, Water LV, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999, 5:1041-1056.
30. Mukaratirwa S, Nederbragt H. Tenascin and proteoglycans: the role of tenascin and proteoglycans in canine tumours. Res Vet Sci 2002, 73:1-8. 10.1016/S0034-5288(02)00066-8, 12208101.
31. Skandalis SS, Labropoulou VT, Ravazoula P, Likaki-Karatza E, Dobra K, Kalofonos HP, Karamanos NK, Theocharis AD. Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer 2011, 11:1-13. 10.1186/1471-2407-11-1, 3128009, 21679412.
32. Voutilainen K, Anttila M, Sillanpää S, Tammi R, Tammi M, Saarikoski S, Kosma VM. Versican in epithelial ovarian cancer: relation to hyaluronan, Clinicopathologic factors and prognosis. Int J Cancer 2003, 107:359-364. 10.1002/ijc.11423, 14506734.
33. Pirinen R, Leinonen T, Böhm J, Johansson R, Ropponen K, Kumpulainen E, Kosma VM. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 2005, 36:44-50. 10.1016/j.humpath.2004.10.010, 15712181.
34. Wu Y, Chen L, Cao L, Sheng W, Yan BB. Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and β1-integrin. J Cell Sci 2004, 117:2227-2237. 10.1242/jcs.01057, 15126624.
35. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 2004, 18:754-756.
36. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005, 15:483-494. 10.1038/sj.cr.7290318, 16045811.
37. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, Pauw ED, Castronovo V. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 2010, 126:640-650. 10.1002/ijc.24812, 19662655.
38. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, Slingerland J, Dumont D, Yang BB. The roles of versican v1 and v2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 2005, 16:1330-1340. 10.1091/mbc.E04-04-0295, 551496, 15635104.
39. Sheng W, Wang G, Pierre DPL, Wen J, Deng Z, Wong CKA, Lee DY, Yang BB. Versican Mediates Mesenchymal-Epithelial Transition. Mol Biol Cell 2006, 17:2009-2020. 10.1091/mbc.E05-10-0951, 1415306, 16452631.
40. Owen LN. The TNM Classification of tumors in domestic animals 1980, 26-32. Organization: World Health.
41. Luna LG. Manual of histologic staining methods of the Armed Forces Institute of Pathology 1968, New York: McGraw Hill.
42. Misdorp W, Else RW, Hellmén E, Lipscomb TP. Histological classification of the mammary tumors of the dog and the cat 1999, 59. Washington: DC: AFIP, WHO International Histological Classification Tumors of Domestic Animals.
43. Elston CW, Ellis IO. Assessment of histological grade, Systemic Pathology 1998, 365-384. Churchill Livingstone, London: ENG, The breast.
44. Dutra AP, Azevedo Júnior GM, Schmitt FC, Cassali GD. Assessment of cell proliferation and prognostic factors in canine mammary gland tumors. Arq Bras Med Vet Zootec 2008, 60:1403-1412.
45. Restucci B, Papparella S, De Vigo G, Maiolino P. E-cadherin expression in normal and neoplastic canine mammary gland. J Comp Pathol 1997, 116:191-202. 10.1016/S0021-9975(97)80076-X, 9131434.
46. Buijs JT, Cleton AM, Smit VTHBM, Löwik CWGM, Papapoulos SE, Van Der Pluijm G. Prognostic significance of periodic acid-Schiff-positive patterns in primary breast cancer and its lymph node metastases. Breast Cancer Res Treat 2004, 84:117-130. 10.1023/B:BREA.0000018408.77854.d1, 14999142.